Please enable JavaScript.
Coggle requires JavaScript to display documents.
Quiz 1 Part 1 - Coggle Diagram
Quiz 1 Part 1
ropinirole (Requip, Requip XL)
common ADRs: dizziness, dyskinesia, nausea, orthostatic hypotension, somnolence, vomiting, hallucinations
rare ADRs: sinus node dysfunction, neuroleptic malignancy syndrome, impulse control/compulsive behaviors
interactions: CYP1A2 inhibitors/inducers, antipsychotics (may decrease effectiveness of antipsychotics and/or dopamine agonists)
efficacy: reduction in rigidity, tremor, gait disturbances; decrease in desire to move limbs
indications: Parkinson disease, restless legs syndrome
toxicity: S/S of postural hypotension, BP, CNS depression/somnolence, decrease HR, periodic dermatologic screening
-
counseling: take with food to reduce nausea; avoid driving and other activities requiring mental alertness or coordination until drug effects are realized; rise slowly from sitting/lying-down position; report new onset or exacerbation of dyskinesia, changes in BP, fainting, or unusual urges; avoid sudden D/C of drug, it increases risk of neuroleptic malignancy syndrome; do not drink EtOH or take other CNS depressants while using this drug
pramipexole (Mirapex, Mirapex ER)
common ADRs: asthenia, dream disorder, dyskinesia, EPS movements, nausea, somnolence
rare ADRs: blackouts, HF, impulsive behavior, melanoma
interactions: cimetidine (increased pramipexole concentrations), antipsychotics (may reduce the effectiveness of antipsychotic or dopamine agonists)
-
indications: Parkinson disease, restless leg syndrome
toxicity: hypotension, drowsiness, hallucinations, or behavior changes; melanoma screening
class: dopamine agonist, antiparkinson
counseling: take with food if nausea occurs; avoid activities requiring mental alertness or coordination until drug effects are realized; rise slowly from a sitting/lying-down position; report new or increased gambling urges, sexual urges, compulsive eating or buying, as well as new-onset or worsening dyskinesia; do not D/C abruptly, as this may cause emergent hyperpyrexia and confusion; do not drink EtOH, and avoid concomitant use of other CNS depressants
carbidopa/levodopa (Rotary, Duopa,
Sinemet)
-
rare ADRs: orthostatic hypotension, neuroleptic malignant syndrome, hallucinations, sleep attacks, compulsive behavior
interactions: dopamine D2 receptor antagonists (isoniazid, metoclopramide; reduction in therapeutic effect of levodopa), linezolid (unknown; serotonin toxicity with severe hypertension), MAOIs (severe hypotension), phenytoin/papaverine/iron salts (reversal of the effects of levodopa in PD), antihypertensives (exacerbate orthostatic hypotension risk)
efficacy: reduction in symptoms of PD (extrapyramidal movements, rigidity, tremor, gait disturbances)
-
toxicity: seek medical attention if GI bleeding, hallucinations, or dyskinesias occur; monitor IOP in glaucoma patients who take this product
-
counseling: if using ODT, place on top of tongue; does not require water or swallowing
memantine (Namenda)
rare ADRs: SJS, DVT, hepatitis, liver failure, CVA, grand mal seizure, TIA, acute renal failure
-
-
-
toxicity: seek medical attention if severe adverse effects occur; BP, eye exams, LFTs, electrolytes, SCr
-
counseling: may be taken with or without food; the oral solution is packaged with a dosing device that should be used to administer the medication
-
donepezil (Aricept)
-
rare ADRs: atrioventricular block, GI bleeding, TdP
interactions: tolterodine/oxybutynin (decreased efficacy of donepezil via cholinergic receptor antagonism by anticholinergic drug), ramelteon (increased ramelteon exposure)
efficacy: improvement in symptoms of Alzheimer-type dementia; however, only slowed decline rather than improvement may be seen
indications: Alzheimer disease, dementia (mild-severe)
-
toxicity: symptoms of active or occult GI bleeding, particularly if patient has history of ulcer disease or is receiving concomitant NSAIDs
counseling: take at bedtime, with or without food; allow disintegrating tablet to dissolve on tongue and follow with glass of water; adverse effects may be more frequent at dose escalation and tend to resolve with continued use; report S/S of GI bleeding